KRMN

Analyst Note: Karman Holdings Inc. (KRMN)

Date: 2026-06-20 Sector: Industrials | Industry: Defense & Space Systems

1. Structural Readiness

• Conservative Entry: $106.22
• Current Price: $50.37
• Extension: -52.6% vs. conservative entry
• Breakout Level: $106.22 (Conservative) / $72.00 (Structural Support)
• ATR Context: ATR at breakout was 5.0% (High/Structural Quality). Current ATR is 8.9% (Extreme).

Analysis:

2. The Thesis Layer

• Primary Secular Theme: Defense Modernization → Precision Munitions (Tier Direct, High Confidence).
• Thesis Exposure: The company is a direct beneficiary of the "Defense Modernization" wave, specifically within the Precision Munitions and Space sectors.
• Context: The thesis is reinforced by the "Artemis II" success and the restructuring of the Artemis program through 2029, which management cites as increasing contracting momentum. The company is positioned to benefit from the FY 2027 defense budget request, which includes sharp procurement funding increases for supported programs.
• Conviction Weighting: The thesis is structurally strong given the "Tier Direct" classification and the high confidence in the secular tailwind. However, the market's reaction (price invalidation) suggests a disconnect between the fundamental thesis and current market pricing, or a specific company-level issue not yet resolved in the public record.

3. The Business

Karman Holdings Inc. specializes in the upfront design, testing, manufacturing, and sale of mission-critical systems for high-priority missile, defense, and space programs.

• Business Model: The company operates on a backlog-driven model with high visibility. As of March 31, 2026, the company reported $723.3 million in remaining performance obligations (RPO). Management expects to recognize approximately 42.0% of these obligations as revenue in the remainder of 2026, with the remainder spread across 2027 and beyond.
• Financial Performance (PIT):
• 2025 Revenue: $471.5 million (36.6% YoY growth).
• 2025 Net Income: $17.4 million.
• 2025 Adjusted EBITDA: $145.3 million (30.8% margin).
• 2026 Guidance (as of May 12, 2026): Full-year revenue expected between $720 million and $735 million, with non-GAAP adjusted EBITDA of $208.5 million to $219.5 million (29.4% margin midpoint).
• Operational Highlights:
• Backlog: Management stated an "all-time high backlog of more than $1 billion" as of May 12, 2026.
• Visibility: Strong backlog combined with Q1 revenue provides approximately 90% visibility to the midpoint of full-year revenue guidance.
• Customer Concentration: As of March 31, 2026, two customers comprised 25.6% and 11.6% of total revenue. Management notes that for 2024 and 2025, no single program accounted for more than 12% of revenue on average.
• Program Mix: Revenue is diversified across three core end markets: Hypersonics & Strategic Missile Defense (32%), Tactical Missiles and Integrated Defense Systems (36%), and Space and Launch (32%).
• Key Programs: Supplies key subsystems for the SLS launch vehicle and Orion capsule; Maritime Defense Systems contributed $26 million from submarine and LCAC programs.

4. Archetype and Conviction

• Archetype: Growth Leader.
• Fit: The company demonstrates classic Growth Leader characteristics: rapid revenue expansion (36.6% YoY in 2025), expanding margins (30.8% EBITDA margin), and a massive, growing backlog ($1B+). The appointment of a new CEO (CODM) on March 23, 2026, suggests a potential inflection point in execution or strategy, though the immediate market reaction has been negative.
• Valuation & Conviction Context:
• Strengths: The fundamental spine is robust. The 90% visibility to guidance and the $1B+ backlog provide a high degree of certainty for near-term revenue. The secular tailwinds (Artemis, FY27 Budget) are structural and long-duration.
• Weaknesses: The setup is INVALIDATED. The price action ($50.37) is decoupled from the fundamental strength ($1B backlog, $735M revenue guidance). The current ATR of 8.9% (Extreme) indicates the market is pricing in significant uncertainty or a specific negative catalyst not yet detailed in the provided evidence.
• Conviction Assessment: While the *business* conviction is high (Growth Leader with strong secular tailwinds), the *setup* conviction is zero due to the invalidated structure. The "Growth Leader" archetype is currently fighting a "structural breakdown" narrative. The extreme volatility (8.9% ATR) suggests the market is in a state of dislocation.

5. Invalidations, Strengtheners, and Gaps

• Invalidation Factors:
• Management downgrading the $720M-$735M revenue guidance or EBITDA margins.
• Loss of key contracts (e.g., Artemis, SLS, or Maritime programs) or significant customer concentration issues.
• Strengthening Factors:
• Confirmation of the FY 2027 budget passing Congress with the requested funding levels.
• Successful integration of the new CEO's strategy leading to margin expansion beyond the 29.4% guidance.
• Evidence Gaps:
• Reason for Decline: The provided evidence explains *why* the business is strong (backlog, guidance), but it does not explicitly state *why* the stock price collapsed from the $106.22 entry to $50.37. The "Missing Evidence" block is empty, but the *reason* for the price action is not in the text.
• New CEO Impact: While the appointment is noted, the specific strategic changes or immediate financial impact of the new CEO (appointed March 23, 2026) are not detailed in the provided transcripts.
• Cash Flow: The evidence mentions acquisitions ($210M net cash acquired), but detailed free cash flow generation or liquidity constraints are not explicitly quantified in the snippets provided.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: $1 billion+ all-time high backlog; 90% visibility to full-year revenue guidance; 36.6% YoY revenue growth in 2025; Direct beneficiary of Artemis and FY27 defense budget increases. Sizing hint: Position size should be zero or minimal until structure is re-established; do not attempt to catch a falling knife on an invalidated coil. Expected path: Management expects revenue to grow to $720M-$735M in 2026 with 29.4% margins; structural implications suggest the backlog will support earnings if execution remains on track. Expected horizon: 12-18 months for the backlog to convert to revenue and for the market to re-price the fundamental strength. Failure mode to watch: A close below $72.00 that persists, or a management downgrade of the 2026 revenue/EBITDA guidance.